Table 1 17β-Hydroxysteroid dehydrogenase (17HSD) types 1 and 2 expression and the 17HSD2/17HSD1 ratio in relation to tumour characteristics and tamoxifen treatment
17HSD1 | 17HSD2 | HSD2/HSD1 | ||||
|---|---|---|---|---|---|---|
<2.3 | >2.3 | <0.28 | >0.28 | <0.2 | >0.2 | |
n =171 | n =59 | n =175 | n =55 | n =154 | n =76 | |
Lymphnode status/tumour size (mm) | ||||||
N−, >20 | 48 (75) | 16 (25) | 47 (73) | 17 (27) | 39 (61) | 25 (39) |
N+, ⩽20 | 50 (72) | 19 (28) | 55 (80) | 14 (20) | 53 (77) | 16 (23) |
N+, <20 | 68 (77) | 20 (23) | 66 (75) | 22 (25) | 54 (61) | 34 (39) |
ER status | ||||||
ER− | 36 (71) | 15 (29) | 42 (82) | 9 (18) | 36 (71) | 15 (29) |
ER+ | 135 (75) | 44 (25) | 133 (74) | 46 (26) | 118 (66) | 61 (34) |
PgR status | ||||||
PR− | 67 (73) | 25 (27) | 73 (79) | 19 (21) | 65 (71) | 27 (29) |
PR+ | 104 (75) | 34 (25) | 102 (74) | 36 (26) | 89 (64) | 49 (36) |
Tamoxifen | ||||||
TAM 2 years | 74 (64) | 41 (36) | 81 (70) | 34 (30) | 76 (66) | 39 (34) |
TAM 5 years | 97 (84) | 18 (16) | 94 (82) | 21 (18) | 78 (68) | 37 (32) |
